MedTrace Logo

PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)

NCT04842331 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-01-12

No results posted yet for this study

Summary

This is an open label controlled household-randomised trial designed to evaluate the efficacy of RESP301 alongside standard of care ("SOC") versus SOC alone.

Conditions

  • Respiratory Viral Infection
  • Respiratory Tract Diseases
  • COVID-19 Respiratory Infection

Interventions

DRUG

RESP301 (a nitric oxide generating solution)

Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.

DRUG

Standard of Care (SOC)

Participants will receive institutional SOC for the treatment.

Sponsors & Collaborators

  • Thirty Respiratory Limited

    lead INDUSTRY

Principal Investigators

  • Onn Min Kon, Professor · Imperial College Healthcare NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04842331 on ClinicalTrials.gov